TABLE 3.
Model | Neoadjuvant group ‐ Fudan cohort (n = 98) | Neoadjuvant group ‐ validation cohort (n = 81) | ||
---|---|---|---|---|
C‐index | AIC | C‐index | AIC | |
OS | ||||
Tumor‐CD9 | 0.604 | 525.52 | 0.588 | 518.49 |
Stroma‐CD9 | 0.579 | 528.24 | 0.592 | 517.30 |
Tumor&Stroma‐CD9 risk level | 0.643 | 518.86 | 0.642 | 506.00 |
TNM stage | 0.624 | 518.79 | 0.604 | 510.02 |
Tumor&Stroma‐CD9 risk level + TNM stage | 0.676 | 512.51 | 0.666 | 502.91 |
RFS | ||||
Tumor‐CD9 | 0.593 | 533.42 | 0.583 | 484.63 |
Stroma‐CD9 | 0.590 | 533.64 | 0.588 | 485.21 |
Tumor&Stroma‐CD9 risk level | 0.643 | 524.59 | 0.637 | 472.79 |
TNM stage | 0.628 | 527.28 | 0.606 | 477.45 |
Tumor&Stroma‐CD9 risk level + TNM stage | 0.680 | 519.53 | 0.665 | 470.73 |
Abbreviations: AIC, Akaike information criterion; C‐index, concordance index; OS, overall survival; RFS, recurrence‐free survival.